Sugiura Takeyuki, Nagano Yuki, Noguchi Yoshie
Discovery Research Laboratory, Tokyo R&D Center, Daiichi Pharmaceutical Co. Ltd, Tokyo, Japan.
Cancer Biol Ther. 2007 Jun;6(6):957-64. doi: 10.4161/cbt.6.6.4192. Epub 2007 Mar 26.
To explore differentially expressed genes involved in non-small cell lung cancer progression, we used the gene expression profile database of various human tissues and identified DDX39, a new member of the DEAD box RNA helicases, showing overexpression in human lung squamous cell carcinoma (LSCC) but not in lung adenocarcinoma (LAC). There existed three types of alternatively spliced DDX39 variants (DDX39-L, -S and -SS), of which only DDX39-L contains all the motifs required for RNA helicase activity. RT-PCR analysis verified the increased expression of DDX39-L in LSCC, but not LAC, cultured cells compared with normal bronchial epithelial cells. A high sequence similarity to UAP56 and punctate nuclear localization pattern of DDX39-L suggest that it plays a role in RNA splicing/export. Recombinant DDX39-L binds RNA, hydrolyzes NTPs in an RNA-dependent manner and unwinds double strand RNA bidirectionally, proving that DDX39 is an RNA helicase. Overexpression of DDX39-L stimulates colony formation of HeLa cells, probably through elevation of a translational level, indicating the biological significance of DDX39 in cancer pathogenesis. Thus, DDX39 is a novel RNA helicase capable of promoting cancer cell growth and, thereby, can be a potential target for development of a therapeutic strategy for LSCC.
为了探索参与非小细胞肺癌进展的差异表达基因,我们使用了各种人类组织的基因表达谱数据库,并鉴定出DDX39,它是DEAD盒RNA解旋酶的一个新成员,在人肺鳞状细胞癌(LSCC)中呈过表达,但在肺腺癌(LAC)中未过表达。存在三种可变剪接的DDX39变体(DDX39-L、-S和-SS),其中只有DDX39-L包含RNA解旋酶活性所需的所有基序。RT-PCR分析证实,与正常支气管上皮细胞相比,DDX39-L在LSCC而非LAC培养细胞中的表达增加。与UAP56的高序列相似性以及DDX39-L的点状核定位模式表明它在RNA剪接/输出中起作用。重组DDX39-L结合RNA,以RNA依赖的方式水解NTP,并双向解开双链RNA,证明DDX39是一种RNA解旋酶。DDX39-L的过表达可能通过提高翻译水平刺激HeLa细胞的集落形成,表明DDX39在癌症发病机制中的生物学意义。因此,DDX39是一种新型的能够促进癌细胞生长的RNA解旋酶,从而可能成为开发LSCC治疗策略的潜在靶点。